AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1460207 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 0
Study 1460207 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (Atrovent nasal spray)
Number of subjects: 0
Study 1460207 — intervention group
Group type: COMPARATOR
Intervention: Methacholine
Number of subjects: 0
Study 1460207 — intervention group
Group type: COMPARATOR
Intervention: Histamine
Number of subjects: 0
Study 6567715 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom instruction
Number of subjects: 490
Study 6567715 — intervention group
Group type: EXPERIMENTAL
Intervention: Media only
Number of subjects: 490
Study 6567715 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 490
Study 31441025 — intervention group
Group type: EXPERIMENTAL
Intervention: QuikClot Combat Gauze (QCG)
Number of subjects: 21
Study 31441025 — intervention group
Group type: COMPARATOR
Intervention: Celox Rapid (CR)
Number of subjects: 21
Study 30278407 — intervention group
Group type: EXPERIMENTAL
Intervention: P(v-a)CO2/C(a-v)O2-targeted therapy
Number of subjects: 228
Study 30278407 — intervention group
Group type: COMPARATOR
Intervention: ScvO2-targeted therapy
Number of subjects: 228
Study 30278407 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 228
Study 26334128 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage (30-min massage after exercise)
Number of subjects: 30
Study 26334128 — intervention group
Group type: COMPARATOR
Intervention: Control (normal passive recovery)
Number of subjects: 30
Study 24595511 — intervention group
Group type: EXPERIMENTAL
Intervention: MBCT + depression relapse active monitoring (DRAM)
Number of subjects: 203
Study 24595511 — intervention group
Group type: COMPARATOR
Intervention: Control (DRAM alone)
Number of subjects: 203
Study 24595511 — intervention group
Group type: EXPERIMENTAL
Intervention: MBCT + DRAM
Number of subjects: 203
Study 22459549 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 50 mg
Number of subjects: 512
Study 22459549 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Number of subjects: 512
Study 22459549 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Number of subjects: 512
Study 22459549 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 400 mg
Number of subjects: 512
Study 22459549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 512
Study 19864449 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid infusion
Number of subjects: 11
Study 19864449 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 11
Study 17572467 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereoscopic three-dimensionality presentation of faces
Number of subjects: 0
Study 17572467 — intervention group
Group type: COMPARATOR
Intervention: Synoptic presentation of faces
Number of subjects: 0
Study 16239885 — intervention group
Group type: EXPERIMENTAL
Intervention: 23.4% sodium chloride solution
Number of subjects: 13
Study 16239885 — intervention group
Group type: COMPARATOR
Intervention: Mannitol
Number of subjects: 13
Study 11929393 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-229 (1.25 mg, 2.5 mg, 5 mg, 10 mg b.d.)
Number of subjects: 324
Study 11929393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324
Study 11929393 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-229
Number of subjects: 324
Study 10048009 — intervention group
Group type: EXPERIMENTAL
Intervention: dorzolamide hydrochloride (Trusopt)
Number of subjects: 120
Study 10048009 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 120
Study 8062495 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination product of trimethoprim (15 mg/kg/day) and sulfamethoxazole (75 mg/kg/day)
Number of subjects: 15
Study 8062495 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who discontinued therapy due to toxicity
Number of subjects: 15
Study 8062495 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with major liver toxicity
Number of subjects: 15
Study 3232130 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (250 mg b.i.d. for 21 months)
Number of subjects: 44
Study 3232130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 30961558 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (Cinema Voice)
Number of subjects: 100
Study 30961558 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100
Study 29582623 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramyocardial autologous bone marrow mononuclear stem cells (BMMNC) grafting combined with CABG
Number of subjects: 20
Study 29582623 — intervention group
Group type: COMPARATOR
Intervention: CABG only (Control)
Number of subjects: 20
Study 26445857 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep chamfer preparation
Number of subjects: 200
Study 26445857 — intervention group
Group type: EXPERIMENTAL
Intervention: Feather edge preparation
Number of subjects: 200
Study 26445857 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 200
Study 24756814 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant external beam radiation therapy (EBRT)
Number of subjects: 141
Study 24756814 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (LSS)
Number of subjects: 141
Study 21850496 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood orange juice (1 L/day for 4 weeks)
Number of subjects: 18
Study 21850496 — intervention group
Group type: COMPARATOR
Intervention: Blond orange juice (1 L/day for 4 weeks)
Number of subjects: 18
Study 20021703 — intervention group
Group type: EXPERIMENTAL
Intervention: Multispecies probiotic (5 g, twice daily for 2 weeks)
Number of subjects: 30
Study 20021703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17612637 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD patients
Number of subjects: 99
Study 17612637 — intervention group
Group type: COMPARATOR
Intervention: Patients without CAD
Number of subjects: 99
Study 17612637 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 99
Study 16096435 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 cycles of epidoxorubicin/docetaxel
Number of subjects: 45
Study 11872201 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg daily) and placebo
Number of subjects: 211
Study 11872201 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate (66 mg daily) and placebo
Number of subjects: 211
Study 11872201 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate (66 mg daily) and folic acid (5 mg daily)
Number of subjects: 211
Study 11872201 — intervention group
Group type: COMPARATOR
Intervention: Two placebos
Number of subjects: 211
Study 9788828 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (L) 50 mg/d
Number of subjects: 16
Study 9788828 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (E) 20 mg/d
Number of subjects: 16
Study 7714227 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (300 mg/day)
Number of subjects: 24
Study 7714227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2806234 — intervention group
Group type: COMPARATOR
Intervention: CONTROL (light work clothing)
Number of subjects: 9
Study 2806234 — intervention group
Group type: EXPERIMENTAL
Intervention: SCBA (light work clothing with open circuit self‐contained breathing apparatus)
Number of subjects: 9
Study 2806234 — intervention group
Group type: EXPERIMENTAL
Intervention: FF (firefighter's turnout gear with SCBA)
Number of subjects: 9
Study 2806234 — intervention group
Group type: EXPERIMENTAL
Intervention: CHEM (chemical protective clothing with SCBA)
Number of subjects: 9
Study 792739 — intervention group
Group type: EXPERIMENTAL
Intervention: parsalmide
Number of subjects: 68
Study 792739 — intervention group
Group type: COMPARATOR
Intervention: indomethacin
Number of subjects: 68
Study 7340881 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide (0.25 mg/kg)
Number of subjects: 6
Study 7340881 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide (0.1 mg/kg)
Number of subjects: 6
Study 7340881 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin alone (1 mg/kg)
Number of subjects: 6
Study 30848803 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure target of less than 120 mm Hg (intervention treatment)
Number of subjects: 466
Study 28017248 — intervention group
Group type: EXPERIMENTAL
Intervention: Apraclonidine 0.5%–1% solution, 2 drops to each eye
Number of subjects: 7
Study 25365779 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Motivational Interviewing (MI)
Number of subjects: 129
Study 25216556 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency rTMS over the right inferior frontal gyrus (IFG)
Number of subjects: 10
Study 25216556 — intervention group
Group type: COMPARATOR
Intervention: Vertex (control stimulation site)
Number of subjects: 10
Study 22690882 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based tailored cessation advice report
Number of subjects: 1758
Study 22690882 — intervention group
Group type: COMPARATOR
Intervention: Web-based non-tailored cessation advice report
Number of subjects: 1758
Study 20004966 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF plus tamoxifen (CAFT or CAF-T)
Number of subjects: 1477
Study 20004966 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF-T
Number of subjects: 1477
Study 17562231 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine (25-30 mg/m² on days 1 and 8 every 3 weeks)
Number of subjects: 39
Study 15160563 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine treatment
Number of subjects: 0
Study 11219633 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate, administered bilaterally for 3 weeks
Number of subjects: 12
Study 11219633 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 12
Study 9728839 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine alone (Group B)
Number of subjects: 78
Study 9728839 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine with 75 microg of clonidine (Group BC)
Number of subjects: 78
Study 9728839 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine with 75 microg of clonidine and 12.5 microg of fentanyl (Group BCF)
Number of subjects: 78
Study 8054251 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (3 mg kg‐1 day‐1)
Number of subjects: 10
Study 8054251 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (3 mg kg‐1 day‐1)
Number of subjects: 10
Study 8054251 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg day‐1)
Number of subjects: 10
Study 8054251 — intervention group
Group type: COMPARATOR
Intervention: Non-NSAID control (paracetamol/acetaminophen)
Number of subjects: 10
Study 3133575 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic natural alpha interferon (IFN) therapy
Number of subjects: 24
Study 3133575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30296709 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise (cycling at 40% of maximum oxygen uptake for 20 min)
Number of subjects: 19
Study 30296709 — intervention group
Group type: COMPARATOR
Intervention: Resting condition
Number of subjects: 19
Study 28538774 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilevel Positive Airway Pressure (BiPAP)
Number of subjects: 20
Study 28538774 — intervention group
Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 20
Study 26122012 — intervention group
Group type: COMPARATOR
Intervention: Cord blood 25(OH)D 25‐50 nmol/L at delivery
Number of subjects: 1040
Study 26122012 — intervention group
Group type: COMPARATOR
Intervention: Cord blood 25(OH)D >50 nmol/L at delivery
Number of subjects: 1040
Study 26122012 — intervention group
Group type: COMPARATOR
Intervention: Cord blood 25(OH)D <25 nmol/L at delivery
Number of subjects: 1040
Study 26122012 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA group (specific intervention not detailed)
Number of subjects: 1040
Study 23458374 — intervention group
Group type: EXPERIMENTAL
Intervention: Antismoking media literacy program (five 1-hour lessons)
Number of subjects: 38
Study 23458374 — intervention group
Group type: COMPARATOR
Intervention: Creative writing control program
Number of subjects: 38
Study 21930067 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation group (supervised physical therapy training for 6 weeks + unsupervised maintenance program for 6 weeks)
Number of subjects: 34
Study 21930067 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 34
Study 21930067 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation group
Number of subjects: 34
Study 21930067 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 21930067 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 19371843 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 10 mg/kg
Number of subjects: 17
Study 19371843 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 20 mg/kg
Number of subjects: 17
Study 19371843 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 30 mg/kg
Number of subjects: 17
Study 19371843 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalational gas requirement
Number of subjects: 17
Study 19371843 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative morphine equivalence requirements
Number of subjects: 17
Study 19371843 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective pain using visual analog scale
Number of subjects: 17
Study 16416228 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose-sorbitol mixture (25 g fructose and 5 g sorbitol)
Number of subjects: 11
Study 16416228 — intervention group
Group type: COMPARATOR
Intervention: Glucose (30 g)
Number of subjects: 11
Study 15580199 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined telephone asthma coaching and monetary incentive
Number of subjects: 527
Study 15580199 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 527
Study 10583701 — intervention group
Group type: COMPARATOR
Intervention: Generic digoxin preparation
Number of subjects: 14
Study 10583701 — intervention group
Group type: COMPARATOR
Intervention: Lanoxin
Number of subjects: 14
Study 8975569 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of amitriptyline, propranolol, and phenazepam for causalgic form
Number of subjects: 0
Study 8975569 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of carbamazepine, propranolol, and phenazepam for neuralgic form
Number of subjects: 0
Study 8975569 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine monotherapy for spastic form
Number of subjects: 0
Study 1829306 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms Recombivax‐HB (Merck Sharpe & Dohme Ltd)
Number of subjects: 0
Study 1829306 — intervention group
Group type: COMPARATOR
Intervention: 20 micrograms Engerix‐B (Smith Kline Biologicals)
Number of subjects: 0
Study 6348635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin E
Number of subjects: 174
Study 6348635 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin E administered early (<12 hours of age)
Number of subjects: 174
Study 6348635 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin E administered after 39 hours of age (mean age 167.5 hours)
Number of subjects: 174
Study 6348635 — intervention group
Group type: COMPARATOR
Intervention: No vitamin E
Number of subjects: 174
Study 6348635 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 174
Study 6348635 — intervention group
Group type: EXPERIMENTAL
Intervention: Early parenteral and oral vitamin E
Number of subjects: 174
Study 31097081 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (Pem)
Number of subjects: 40
Study 31097081 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed plus Bevacizumab (Pem + Bev)
Number of subjects: 40
Study 30355096 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-factor prothrombin complex concentrate and vitamin K infusion followed by intravenous thrombolysis (IVT)
Number of subjects: 26
Study 27400075 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecnis Multifocal Toric IOL
Number of subjects: 30
Study 24615354 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-intensity leisure-time physical activity (LTPA)
Number of subjects: 399
Study 24615354 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous-intensity leisure-time physical activity (LTPA)
Number of subjects: 399
Study 24615354 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of light-intensity LTPA
Number of subjects: 399
Study 24615354 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of moderate-to-vigorous-intensity LTPA
Number of subjects: 399
Study 24615354 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors encouraging LTPA
Number of subjects: 399
Study 24615354 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to LTPA
Number of subjects: 399
Study 24615354 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors for maintaining LTPA during pregnancy
Number of subjects: 399
Study 24615354 — intervention group
Group type: EXPERIMENTAL
Intervention: Common barriers to LTPA
Number of subjects: 399
Study 21775117 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus a medical food containing soy protein and plant sterols (n=20)
Number of subjects: 35
Study 21775117 — intervention group
Group type: COMPARATOR
Intervention: Diet only (n=15)
Number of subjects: 35
Study 21093036 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 106
Study 21093036 — intervention group
Group type: COMPARATOR
Intervention: Control (previous treatment alone)
Number of subjects: 106
Study 18533779 — intervention group
Group type: COMPARATOR
Intervention: Coronally positioned flap plus acellular dermal matrix (ADM)
Number of subjects: 24
Study 18533779 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronally positioned tunnel technique plus acellular dermal matrix (ADM)
Number of subjects: 24
Study 15672113 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogurt (1100 mg Ca/day)
Number of subjects: 34
Study 15672113 — intervention group
Group type: COMPARATOR
Intervention: Control (400‐500 mg Ca/day)
Number of subjects: 34
Study 12804845 — intervention group
Group type: EXPERIMENTAL
Intervention: INFLUSOME-VAC (IL-2-supplemented trivalent liposomal influenza vaccine)
Number of subjects: 81
Study 12804845 — intervention group
Group type: COMPARATOR
Intervention: Standard trivalent split virion vaccine (control)
Number of subjects: 81
Study 12804845 — intervention group
Group type: EXPERIMENTAL
Intervention: INFLUSOME-VAC
Number of subjects: 81
Study 12804845 — intervention group
Group type: COMPARATOR
Intervention: INFLUSOME-VAC and Standard vaccine
Number of subjects: 81
Study 10372695 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone patch
Number of subjects: 108
Study 10372695 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 108
Study 10829968 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) latex agglutination test
Number of subjects: 0
Study 10829968 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) CRP test
Number of subjects: 0
Study 10829968 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF CRP test
Number of subjects: 0
Study 1866542 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime plus amikacin
Number of subjects: 0
Study 1866542 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime plus vancomycin
Number of subjects: 0
Study 6347748 — intervention group
Group type: EXPERIMENTAL
Intervention: Quazepam 15 mg
Number of subjects: 36
Study 6347748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 31282169 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic physical exercise program (3 sessions per week)
Number of subjects: 129
Study 31282169 — intervention group
Group type: COMPARATOR
Intervention: Routine prenatal care
Number of subjects: 129
Study 28017756 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand-alone intervertebral spacer with integrated screw fixation
Number of subjects: 54
Study 28017756 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical plate and spacer construct
Number of subjects: 54
Study 26966919 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous abatacept
Number of subjects: 1137
Study 24666729 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous BFR
Number of subjects: 43
Study 24666729 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent BFR
Number of subjects: 43
Study 24666729 — intervention group
Group type: COMPARATOR
Intervention: Control (exercise without BFR)
Number of subjects: 43
Study 24666729 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (after 5-week training)
Number of subjects: 43
Study 21537928 — intervention group
Group type: EXPERIMENTAL
Intervention: ICE
Number of subjects: 10
Study 21537928 — intervention group
Group type: EXPERIMENTAL
Intervention: HEAT
Number of subjects: 10
Study 21537928 — intervention group
Group type: COMPARATOR
Intervention: CONT
Number of subjects: 10
Study 20398248 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry powder standardized for proanthocyanidin content (72 mg of PAC per day)
Number of subjects: 32
Study 20398248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 18590519 — intervention group
Group type: COMPARATOR
Intervention: Abrupt strategy (olanzapine discontinued at risperidone initiation)
Number of subjects: 123
Study 18590519 — intervention group
Group type: COMPARATOR
Intervention: Gradual 1 strategy (olanzapine at 50% entry dose for 1 week after risperidone initiation)
Number of subjects: 123
Study 18590519 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual 2 strategy (olanzapine at 100% entry dose for 1 week, then at 50% in the second week)
Number of subjects: 123
Study 18590519 — intervention group
Group type: EXPERIMENTAL
Intervention: All strategies (switching from olanzapine to risperidone)
Number of subjects: 123
Study 15971073 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium ferric gluconate complex (SFGC) therapy at 1.5 mg kg(‐1)
Number of subjects: 66